Andreas Ritsch

List of Publications by Year
in descending order

74 papers	2,447 citations	201385 27 h-index	214527 47 g-index
75 all docs	75 docs citations	75 times ranked	3681 citing authors

#	Article	IF	Citations
1	Cadmium Is a Novel and Independent Risk Factor for Early Atherosclerosis Mechanisms and In Vivo Relevance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1392-1398.	1.1	245
2	HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology, 2017, 106, 663-675.	1.5	186
3	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal, 2015, 36, ehv352.	1.0	116
4	High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. European Heart Journal, 2013, 34, 3563-3571.	1.0	110
5	Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography. Circulation, 2010, 121, 366-374.	1.6	97
6	The Neuropeptide Secretoneurin Acts as a Direct Angiogenic Cytokine In Vitro and In Vivo. Circulation, 2004, 109, 777-783.	1.6	92
7	Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. European Heart Journal, 2017, 38, 1597-1607.	1.0	77
8	Determinants of cholesterol efflux capacity in humans. Progress in Lipid Research, 2018, 69, 21-32.	5.3	77
9	Relationship of Plasma Cholesteryl Ester Transfer Protein to HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1430-1436.	1.1	76
10	Selective imaging of saturated and unsaturated lipids by wide-field CARS-microscopy. Optics Express, 2008, 16, 2699.	1.7	68
11	Hypoxia upâ€regulates the angiogenic cytokine secretoneurin via an HIFâ€1Î±â€and basic FGFâ€dependent pathway in muscle cells. FASEB Journal, 2007, 21, 2906-2917.	0.2	62
12	Structure-function relationships of HDL in diabetes and coronary heart disease. JCI Insight, 2020, 5, .	2.3	62
13	Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis, 2008, 196, 219-226.	0.4	48
14	Gene Therapy With the Angiogenic Cytokine Secretoneurin Induces Therapeutic Angiogenesis by a Nitric Oxideâ€“Dependent Mechanism. Circulation Research, 2009, 105, 994-1002.	2.0	47
15	Kinetics of lipids, apolipoproteins, and cholesteryl ester transfer protein in plasma after a bicycle marathon. Metabolism: Clinical and Experimental, 1994, 43, 633-639.	1.5	45
16	The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice. PLoS ONE, 2010, 5, e8722.	1.1	45
17	Ursolic acid causes DNA-damage, P53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis, 2011, 219, 402-408.	0.4	45
18	Cholesteryl Ester Transfer Protein in Metabolic Syndrome. Obesity, 2006, 14, 812-818.	1.5	41

#	Article	IF	Citations
19	Deficiency of Cholesteryl Ester Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3433-3441.	1.1	39
20	EFFECT OF PANCREAS TRANSPLANTATION ON LIPOPROTEIN LIPASE, POSTPRANDIAL LIPEMIA, AND HDL CHOLESTEROL. Transplantation, 1994, 58, 899-904.	0.5	38
21	Alternative Splicing of Vasohibin-1 Generates an Inhibitor of Endothelial Cell Proliferation, Migration, and Capillary Tube Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 478-484.	1.1	37
22	The Taq1Bâ€variant in the Cholesteryl Esterâ€“Transfer Protein Gene and the Risk of Metabolic Syndrome. Obesity, 2008, 16, 919-922.	1.5	36
23	Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein. Atherosclerosis, 2011, 219, 109-115.	0.4	35
24	A Novel Candidate for Prevention and Treatment of Atherosclerosis: Urolithin B Decreases Lipid Plaque Deposition in apoE^{â^'/â^'} Mice and Increases Early Stages of Reverse Cholesterol Transport in oxâ€ŁLDL Treated Macrophages Cells. Molecular Nutrition and Food Research, 2019, 63, e1800887.	1.5	32
25	Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrology Dialysis Transplantation, 2007, 23, 321-327.	0.4	31
26	The thyromimetic T-0681 protects from atherosclerosis. Journal of Lipid Research, 2009, 50, 938-944.	2.0	29
27	Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via <scp>CXCR</scp>2. EMBO Molecular Medicine, 2014, 6, 810-820.	3.3	29
28	High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality. Clinical Chemistry, 2017, 63, 1886-1896.	1.5	28
29	HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study. Scientific Reports, 2020, 10, 19223.	1.6	27
30	Effects of Weight Loss on Lipid Transfer Proteins in Morbidly Obese Women. Lipids, 2009, 44, 1125-30.	0.7	26
31	Scavenger receptor class B type I polymorphisms and peripheral arterial disease. Metabolism: Clinical and Experimental, 2007, 56, 1135-1141.	1.5	25
32	Cholesteryl ester transfer protein in patients with coronary heart disease. European Journal of Clinical Investigation, 2010, 40, 616-622.	1.7	25
33	Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. European Journal of Clinical Investigation, 2014, 44, 395-401.	1.7	25
34	Insulin improves fasting and postprandial lipemia in type 2 diabetes. European Journal of Internal Medicine, 2002, 13, 256-263.	1.0	23
35	Reduced Plasma High-Density Lipoprotein Cholesterol in Hyperthyroid Mice Coincides with Decreased Hepatic Adenosine 5â€²-Triphosphate-Binding Cassette Transporter 1 Expression. Endocrinology, 2008, 149, 3708-3712.	1.4	23
36	The polyphenol PGG enhances expression of SR-BI and ABCA1 in J774 and THP-1 macrophages. Atherosclerosis, 2015, 242, 611-617.	0.4	23

#	Article	IF	Citations
37	Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I. Journal of Molecular Medicine, 2005, 83, 927-932.	1.7	22
38	Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein. Journal of Lipid Research, 2002, 43, 636-645.	2.0	22
39	Aspirin regulates expression and function of scavenger receptorâ€BI in macrophages: studies in primary human macrophages and in mice. FASEB Journal, 2006, 20, 1328-1335.	0.2	19
40	The resurgence of thyromimetics as lipid-modifying agents. Current Opinion in Investigational Drugs, 2009, 10, 912-8.	2.3	19
41	Phospholipid Transfer Protein Augments Apoptosis in THP-1â€“Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 908-915.	1.1	18
42	Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Current Opinion in Lipidology, 2003, 14, 173-179.	1.2	16
43	Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE â^'/â^' mice. Journal of Molecular and Cellular Cardiology, 2016, 99, 35-46.	0.9	16
44	Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein. Journal of Lipid Research, 2002, 43, 636-45.	2.0	16
45	Knockout of Apolipoprotein E in rabbit promotes premature intervertebral disc degeneration: A new in vivo model for therapeutic approaches of spinal disc disorders. PLoS ONE, 2017, 12, e0187564.	1.1	15
46	HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men. Atherosclerosis, 2018, 274, 23-28.	0.4	15
47	Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Biomedicines, 2020, 8, 524.	1.4	15
48	Adipocyte GPX4 protects against inflammation, hepatic insulin resistance and metabolic dysregulation. International Journal of Obesity, 2022, 46, 951-959.	1.6	15
49	Quantification of Low-Density and High-Density Lipoproteins in Human Serum by Material Enhanced Infrared Spectroscopy (MEIRS). Current Medicinal Chemistry, 2009, 16, 4601-4608.	1.2	13
50	APOE-knockout in rabbits causes loss of cells in nucleus pulposus and enhances the levels of inflammatory catabolic cytokines damaging the intervertebral disc matrix. PLoS ONE, 2019, 14, e0225527.	1.1	12
51	Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clinical Chemistry and Laboratory Medicine, 2004, 42, 247-55.	1.4	11
52	The MTP â^'493TT genotype is associated with peripheral arterial disease: Results from the Linz Peripheral Arterial Disease (LIPAD) Study. Clinical Biochemistry, 2008, 41, 712-716.	0.8	11
53	Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits. Atherosclerosis, 2012, 222, 360-366.	0.4	11
54	Cholesteryl ester transfer protein gene expression is not specifically regulated by CCAAT/Enhancer-binding protein in HepG2-cells. Atherosclerosis, 1999, 146, 11-18.	0.4	10

#	Article	IF	Citations
55	Enhancement of cholesteryl ester transfer in plasma by hormone-replacement therapy. Metabolism: Clinical and Experimental, 2002, 51, 599-604.	1.5	10
56	A gel filtration assay to determine glycogen synthase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 820, 143-145.	1.2	9
57	In vivo application of adenoviral vectors purified by a Taqman Real Time PCR-supported chromatographic protocol. International Journal of Biological Macromolecules, 2006, 39, 77-82.	3.6	9
58	Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Atherosclerosis, 2020, 311, 84-90.	0.4	9
59	Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Atherosclerosis, 1995, 117, 253-261.	0.4	8
60	Pancreas transplantation modulates reverse cholesterol transport. Transplant International, 1999, 12, 360-364.	0.8	8
61	Expression, Purification, and Biochemical Characterization of Human Afamin. Journal of Proteome Research, 2018, 17, 1269-1277.	1.8	8
62	Pancreas transplantation modulates reverse cholesterol transport. Transplant International, 1999, 12, 360-364.	0.8	7
63	Influence of aspirin on SR-BI expression in human carotid plaques. Atherosclerosis, 2009, 206, 234-238.	0.4	6
64	Matcha Green Tea Powder does not Prevent Dietâ€Induced Arteriosclerosis in New Zealand White Rabbits Due to Impaired Reverse Cholesterol Transport. Molecular Nutrition and Food Research, 2021, 65, e2100371.	1.5	6
65	Hepatic ENPP1 expression is induced in diabetic rabbits. Mammalian Genome, 2006, 17, 886-891.	1.0	5
66	The K121Q polymorphism of ENPP1 and peripheral arterial disease. Heart and Vessels, 2008, 23, 104-107.	0.5	5
67	Cholesterol Efflux Capacity. Journal of the American College of Cardiology, 2016, 67, 2488-2491.	1.2	5
68	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	1.7	2
69	J-shaped association between circulating apoC-III and cardiovascular mortality. European Journal of Preventive Cardiology, 2022, 29, e68-e71.	0.8	2
70	Cholesterol Efflux Capacity Associates with the Ankle-Brachial Index but Not All-Cause Mortality in Patients with Peripheral Artery Disease. Diagnostics, 2021, 11, 1407.	1.3	2
71	Detecting Cholesteryl Ester Transfer Protein in Plasma. , 2001, 52, 61-76.		0
72	Comment on â€˜Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbitsâ€™ by Zhao et al. (Clin Chim Acta 2006; 365: 119â€“24). Clinica Chimica Acta, 2006, 373, 193.	0.5	0

#	Article	IF	Citations
73	Thyroid Hormones and Lipid Metabolism: Thyromimetics as Anti-Atherosclerotic Agents?. , 2009, , 251-282.		0
74	Thyroid hormone analogues to treat dyslipidemia. Clinical Lipidology, 2010, 5, 477-480.	0.4	0